Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Neogenomics Inc (NEO)

Neogenomics Inc (NEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,177,530
  • Shares Outstanding, K 123,122
  • Annual Sales, $ 444,450 K
  • Annual Income, $ 4,170 K
  • 60-Month Beta 0.64
  • Price/Sales 8.76
  • Price/Cash Flow 71.67
  • Price/Book 3.42
Trade NEO with:

Options Overview Details

View History
  • Implied Volatility 57.70%
  • Historical Volatility 48.57%
  • IV Percentile 90%
  • IV Rank 56.77%
  • IV High 73.33% on 11/30/21
  • IV Low 37.17% on 09/16/21
  • Put/Call Vol Ratio 0.23
  • Today's Volume 37
  • Volume Avg (30-Day) 680
  • Put/Call OI Ratio 5.39
  • Today's Open Interest 3,983
  • Open Int (30-Day) 4,834

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.17
  • Number of Estimates 3
  • High Estimate -0.14
  • Low Estimate -0.21
  • Prior Year 0.12
  • Growth Rate Est. (year over year) -241.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.66 +15.37%
on 12/06/21
44.26 -22.68%
on 11/10/21
-9.37 (-21.50%)
since 11/08/21
3-Month
29.66 +15.37%
on 12/06/21
54.74 -37.49%
on 10/01/21
-16.64 (-32.72%)
since 09/08/21
52-Week
29.66 +15.37%
on 12/06/21
61.57 -44.42%
on 02/16/21
-14.25 (-29.40%)
since 12/08/20

Most Recent Stories

More News
NeoGenomics is Now Oversold (NEO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

NEO : 34.18 (+0.74%)
NeoGenomics To Participate In The Stephens Annual Investment Conference 2021

FT. MYERS, FL / ACCESSWIRE / November 30, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...

NEO : 34.18 (+0.74%)
NeoGenomics Appoints Dave Daly to Its Board of Directors

FT. MYERS, FL / ACCESSWIRE / November 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has appointed...

NEO : 34.18 (+0.74%)
Genetron Health Establishes Strategic Partnership with NeoGenomics to Drive Global Oncology Drug Research and Development

BEIJING, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology...

GTH : 8.00 (-0.74%)
NEO : 34.18 (+0.74%)
NeoGenomics (NEO) Reports Q3 Loss, Lags Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and -1.67%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

NEO : 34.18 (+0.74%)
NeoGenomics Reports Revenue of $121 Million in the Third Quarter

Third-Quarter 2021 Results and Highlights: - Consolidated revenue of $121 million, comprised of Clinical Services revenue of $102 million and Pharma Services revenue of $19 million - Consolidated revenue...

NEO : 34.18 (+0.74%)
NeoGenomics Announces Leadership Team Transition

FT. MYERS, FL / ACCESSWIRE / November 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today...

NEO : 34.18 (+0.74%)
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

Sector ETF report for PSCH

PSCH : 175.78 (+0.14%)
OMCL : 181.81 (+1.71%)
AMN : 113.44 (+1.02%)
NEO : 34.18 (+0.74%)
XLV : 133.42 (+0.47%)
VHT : 254.63 (+0.63%)
NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays

Two clinical studies including interventional RaDaR™ study FT. MYERS, FL / ACCESSWIRE / October 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services...

NEO : 34.18 (+0.74%)
NeoGenomics Schedules its Third Quarter 2021, Earnings Release for November 4, 2021

FT. MYERS, FL / ACCESSWIRE / October 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans...

NEO : 34.18 (+0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology...

See More

Key Turning Points

3rd Resistance Point 36.83
2nd Resistance Point 35.83
1st Resistance Point 34.88
Last Price 34.18
1st Support Level 32.93
2nd Support Level 31.93
3rd Support Level 30.98

See More

52-Week High 61.57
Fibonacci 61.8% 49.38
Fibonacci 50% 45.61
Fibonacci 38.2% 41.85
Last Price 34.18
52-Week Low 29.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar